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Tropical eosinophilia, an occult form of filariasis, results from immunologic            hyperresponsiveness to the human
filarial parasites, Wuchereria bancrofti and Brugia malayi.The clinical syndrome is characterised by cough, dyspnoea,
nocturnal wheezing and chest discomfort and is occasionally accompanied by constitutional symptoms such as weight
loss, anorexia and fever.Chest radiographs show-diffuse reticulo-nodular infiltrates and pulmonary function reveals
restrictive ventilatory defect with mild obstruction.Laboratory studies are characterised by marked peripheral blood
eosinophilia and high serum levels of IgE and filaria-specific IgG and IgE antibodies.The hallmark of the syndrome is
markedly elevated eosinophils in the lower respiratory tract and interstitial lung fibrosis develops if left untreated.
Although patients respond rapidly following a standard 3-week course of diethylcarbamazine, there is incomplete
reversal-of clinical, hematological, radiological, physiological and pathological changes despite treatment.Therefore
other therapeutic modalities such as the addition of corticosteroids to the DEC regimen have to be evaluated in
controlled clinical trials.
 Introduction Aetiology        
Tropical eosinophilia (TE), one of the
main causes of pulmonary eosinophilia in
tropical countries; is prevalent in filarial
endemic regions of the world especially
South-East Asia1. Even though tropical
eosinophilia as a clinical entity was
described only in 1940s, the earliest report
  that conformed to the clinical picture of TE
was published in 1916 by Low2 in a 30-
year-old male. Subsequently, Roy and
Bose3 noticed marked leucocytosis and
eosinophilia in a group of “asthmatic”
subjects who responded to subcutaneous
or intramuscular injections of soamin.
Frimodt - Moller and Barton4 in 1940
described a group of sanatorium patients
in Madanappalle who had extensive
biateral, evenly distributed miliary mottling
   in chest X-rays resembling miliary
tuberculosis. and blood eosinophilia. They
termed this condition as “a pseudo-
tuberculosis condition associated with
eosinophilia”. The name “Tropical
eosinophilia” was coined in 1943 by
Weingarten5 who accidentally observed
that these patients could be treated with
neoarsphenamine, as one of his patients
with concurrent syphilis was cured of his
TE on being given neoarsphenamine for
syphilis.
Various studies6,7 had shown that
filarial infection is the cause of TE. It has
been observed that TE is most frequently
encountered in those regions where
filariasis is endemic1,8.
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A positive filarial complement fixation
test (FCFT) in most patients with TE was
described by Dhanaraj6 nd many
workers used the positive FCFT and
intradermal skin tests using D.immitis
antigen as a diagnostic test for TE9.
Webb et all10 in 1960 demonstrated
microfilariae in the lungs, liver and lymph
nodes of patients with TE.The
microfilariae were sheathed and had the
anatomical features of Wuchereria
bancroft i .  U d w a d i a8 a l so  had
demonstrated microfilariae
(indistinguishable from Brugia malayi) in
open lung biopsy specimens from TE
patients. Elevated concentrations of
filarial-specific IgE have also been
reported in TE11. The observation that
diethylcarbamazine (DEC), an antifilarial
drug, is useful in the treatment12,13 further
supports the hypothesis of a filarial
etiology in TE. Experimental studies
carried out in human voIunteers14,15 had
suggestedthat TE is due to immunologic
hyperresponsiveness to human filariasis.
Leucocyte adhesion phenomenon16 a d
the demonstration that basophils from
patients with TE released greater
amounts of histamine when cells were
challenged with Brugia or Wuchereria
antigens than with Dirofilaia antigens17
provide further evidence that human
forms rather than animal filaria are
responsible for TE.
Pathogenesis
Histopathological findings such as
widely scattered nodules of varying size
(1 to 5mm) over lung surface were first
described by Viswanathan18 a n d
Dhanaraj19. Detailed histopathological
studies demonstrating eosinophilic,
histiocytic and mixedcell type infiltrations
were documented by Udwadia8. He had
clearly shown that pulmonary fibrosis
developed in some patients, particularly
in those with a long-standing history8,20.
Poh21 had noticed mild to moderate
thickening of both pulmonary arteries and
veins in a patient with TE. The current
concept of the pathogenesis of TE 
suggests that it begins. with a lung
parenchymal inflammation in individuals
highly sensitized immunologically to filarial
parasites. The microfilariae released from
lymphatic dwelling adult worm is cleared
in the pulmonary circulation and the
microfilariae degenerate and release their
antigenic constituents which trigger the
local inflammaiory and immune
processes10,17,20. Morphologically, it had
been shown that there was evidence of
degenerating microfilariae and diffuse
inflammation in the lung
parenchyma8,10,22,23. Therefore, it can be
reasonably hypothesized that the clinical
and pulmonary physiological
bnormalities in TE are at least in part due
to accumulation of inflammatory cells in
the lung parenchyma.
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Bronchoalveolar lavage studies had
demonstrated that TE was characterized
by intense eosinophilic inflammatory
process in the lower respiratory tract24.
The concentration of eosinophils in the
epithelial lining fluid (ELF) of the tower
respiratory, tract was many fold greater
than that in the blood, suggesting that
eosinophils accumulate se!ectively in the
lung parenchyma. Electron microscopic
 examinations disclosed   marked
alterations consisting of severe
degranulation with loss of both the cores
and the peripheral portions of the granules.
These findings suggest that eosinophils
are in an activated state. The significant
negative correlation of lung eosinophils
with transfer factor25 is, therefore,
compatible with the hypothesisthat the
toxic mediators liberated- by activated
eosinophils are responsible for the injury
to the lung parenchyma in TE. Polyclonal
IgE and parasite - specific IgG, IgM and
IgE antibody levels in epithelial lining fluid
(ELF) were significantly higher in TE
patients25. Treatment with DEC 6 - 14
days later showed a dramatic fall in the
levels of ELF parasite-specific IgG and
IgE antibodies without corresponding
changes in either the serum antibody
levels or ELF polyclonal immunoglobulin
levels. lmmunoblot comparison of the
antigen recognition pattern of ELF and
serum antibodies demonstrated a general
similarity in parasite antigen recognized.
Thus. a profound antibody response to 
filarial infection is found in the lungs of
patients with TE, suggesting that these
filaria specific antibodies play an important
role in the pathogenesis of this disorder25.
Clinical features and
management
TE is predominantly seen in males
and between the ages of 15 and 40
years1. Udwadia8 had classified the clinical
manifestations into 6 forms. They are
respiratory form which is the commonest
form, alimentary form, general form.
lymphatic form, mixed form and
asymptomaticform with only peripheral
eosinophilia. Respiratory form is
characterisedby cough, dyspnoea and
nocturnalwheez ing , occasionally
associated with fever, anorexia and weight
loss. Clinical examination may reveal
rales and rhonchi. Leucocytosis with an
absolute increase in eosinophils in the
peripheral blood is the hallmark of TE4,5.
Microfilariae are rarely seen in the
peripheral blood8. Sputum shows clumps
of eosinophils and Charcot-Leyden
crystals5. Radiological features in TE
include miliary mottling, prominent hila
with increased vascular markings. In
patients with long-standing history. lung
fields may show reticulations and in a few
cases honeycombing2O. Chest
radiographs may be normal in 20-30% of
patients with TE8. Before treatment, the
main physiological abnormality in acute
TE was a reduction in the carbonmonoxide
transfer factor21,27 which was found to be
due to reduction in membrane diffusing
capacity (Dm)28. Mild to moderate
obstructive ventilatory defect was seen in
30% of cases and restrictive defect in 50-
70%20,29. Arterial hypoxemia (PaO2 < 80
mm Hg) was observed in 42% of acute TE
patients, but 36% had only mild hypoxemia
(PaO2, 70-80 mm Hg)
29,30.
The diagnostic criteria, of TE,
therefore, include history of past orpresent
residence in the endemic areas of filariasis,
respiratory symptoms, pulmonary
infiltrates, peripheral blood eosinophils >
2000 cells/mm3 and high serum antifilarial
IgG. Initially, the treatment of TE was with
arsenic and was abandoned because of
its toxicity5. Later on, diethylacarbamazine
(DEC), a piperazine derivative with
antifilarial activity was found to be the
drug of choice12,13,31 and it is cheap and
least toxic. The recommended schedule
of treatment with DEC is 6mg/kg body
weight for 3 weeks32,33. Most individuals
with TE respond to DEC within 1 to 3
weeks with a progressive reduction in
symptoms, clearing of the chest X-rays,
reduction in the blood eosinophil count,
and improvement in lung function.
Relapses occurred in 20% of patients
followed up for 5 years8. Earlier workers34
had shown that steroids were also effective
in the treatment of TE. The new antifilarial
drug, Ivermectin given in a dosage of
200 ug/kg/day for 2 days was found to be 
ineffective in TE (Personal observations-
unpublished.
It had been shown previously that
acute tropical eosinophilia left untreated
could develop into chronic interstitial lung
disease’.Studies conducted to know the
fate of those patients who were treated
“successfuIly” with a standard three weeks
course of DEC had revealed that most
patients had shown a marked symptomatic
improvement, but peripheral blood
eosinophilia (> 2000 cells/cc) persisted in
52%, radiographic abnormalities in 44%,
cough in 22% and chest signs in 8%29.
Significant improvement was noticed in
almost all aspects of lung function including
blood gases, but the mean values for
forced expiratory volume in one second
(FEV1), transfer factor (TLCO), transfer
coefficient (KCO) and membrane diffusing
capacity(Dm) continued to be significantly
lower than predicted values20,21,29. At one
month the obstructive defect was
persistent in 14% and the restrictive in
16%. Reduced transfer factor and transfer
coefficient persisted in 62% and 54%
respectively. There was also a marked
decrease of the lung eosinophils35
following the treatment. However, a mild
macrophage-eosinophilic alveolitis was
presisting at one month despite
treatment=. Thus, there was incomplete
reversal of clinical, hematological,
radiological, physiological and
pathological changes in TE one month
after starting a 3-week course of
d i e t h y l c a r b a m a z i n e2 9 , 3 5. 
The observation that there is
incomplete recovery in TE29 suggests the
possibility that the disease can persist
despite DEC therapy and lead to chronic
dyspnoea with restrictive functional
impairment. Majority of patients evaluated
12±2 months later following a standard 3-
week course of DEC for acute TE36 had
mild, pesistent symptoms referable to
the lung, chest X-ray abnormalities, blood
eosinophilia and elevated serum IgE and
filarial specific IgG35. On the average,
lung function was consistent with the
presence of chronic, mild interstitial lung
disease. When theinflammatory cells
from the lower respiratory tract were
examined, there was a persistent
eosinophilic alveolitis36. A oneyear follow
up study of  50patients had‘ revealed that
Course of disease
chronic eosinophilic alveolitis in 35% and
diffusion defect in 51% could occur at 12
months despite treatment37. Evaluation
of the lower respiratory tract inflammatory
cells recovered from post-DEC - treated
individuals demonstrated spontaneous
release of exaggerated amounts of O2
and H2O2 compared to normal subjects
36.
Treatment with prednisone significantly
reduced the lower respiratory tract
eosinophil inflammation and the release
of oxidants38.
These findings suggest that standard
treatment as practiced currently ie one
course DEC (6 mg/kg/body weight) for 3
weeks is inadequate for a cure in TE.
Therefore, other modalities of treatment
such as long-term DEC with or without
corticosteroids have to be evaluated in a
controlled clinical trial.
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